Clinical Trial Update: An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy [Phase 2, Phase 3]

View source ↗

Summary

An open Phase 2/3 trial assessing the tolerability of AVANZ Olive Immunotherapy in allergic rhinitis due to olive pollen has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• AVANZ Olive Immunotherapy

Snippet

Sponsor: ALK-Abelló A/S | Conditions: Allergic Rhinitis Due to Olea Europaea Pollen | Phase 2, Phase 3 | Status: COMPLETED